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BACKGROUND: Patients receiving cytotoxic therapy for solid tumours are at risk of severe influenza. However, few data are available
regarding the immunogenical efficacy of influenza vaccine in these patients.
METHODS: In this prospective study, 25 patients with breast (n¼13) or prostate (n¼12) cancer received a trivalent inactivated
influenza vaccine along with docetaxel (Taxotere) administration. The influenza virus type A and B antibody titres were measured
using haemagglutinin inhibition (Garten et al, 2009) before and 21 days after the vaccination. Seroconversion rate was defined as the
percentage of patients with an increase in the serum titres X4 after vaccination.
RESULTS: Median age was 65 years (range: 33–87 years); 52% were females. Seroconversion rates were low: 28% (95% CI: 23.1–33.3)
for H1N1, 8% (95% CI: 7.7–8.3) for H3N2 and 16% (95% CI: 7.7–25) for the B strain. The geometric mean titres ratios were 2.16
(H1N1), 1.3 (H3N2) and 1.58 (B). No serious adverse event (AE) related to the vaccine was reported. All the reported AE were
from mild-to-moderate intensity.
CONCLUSION: In the patients receiving docetaxel for solid tumours, influenza vaccine triggers an immune response in only one third.
Strategies using more immunogenic influenza vaccines must be evaluated in such patients.
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Influenza is a common respiratory infectious disease, which
operates in an epidemic mode. It is responsible for secondary
bacterial infections of lower respiratory tract causing a sharp
increase in morbidity and mortality (Simonsen et al, 2000;
Thompson et al, 2004). Infants, young children, the elderly,
pregnant women, but also individuals with chronic disease or
underlying immunosuppression are considered at increased risk of
death or complications from seasonal influenza (Neuzil et al, 2000;
Cooksley et al, 2005; Fiore et al, 2007). In patients with cancer,
influenza-associated infections cause mortality estimated at 9%,
which is significantly higher than the mortality in the general
population. The overall case-fatality rate is considered to be low on
average (o0.1%), but is higher in vulnerable populations like
elderly people (approaching 1%) and in patients with chronic
underlying conditions (Foppa and Hossain, 2008; Nogueira
et al, 2009). In addition, infectious events may postpone the
administration of chemotherapy, lowering dose intensity and
thereby being detrimental to the care of cancer patients.
Influenza vaccination is an effective means of preventing
influenza and its complications. It allows a reduction of morbidity
and mortality secondary to influenza, and is cost-effective in
healthy adults (Demicheli et al, 2000).
Influenza vaccines are mostly inactivated vaccines, composed of
three influenza viruses strains selected annually on the basis of
epidemiological data by annual WHO recommendations, two
influenza A and one B virus. A vaccine dose contains 15mgo f
haemagglutinin for each strain and is given intramuscularly or
subcutaneously.
Influenza vaccination is recommended by several health
authorities in immunosuppressed patients, including patients
receiving chemotherapy (Fiore et al, 2007). Despite these
recommendations, the rate of influenza vaccination coverage
among patients at high risk of complications, including patients
with cancer, heart condition, diabetes, chronic respiratory disease
or renal failure, is very low: 25% of adults between 18 and 64 years
in the United States (18% among 18–49 years to 32% in 50–64
years) (Fiore et al, 2007). In France, we recently showed a similar
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scoverage of flu vaccination in patients with cancer (30%)
(Loulergue et al, 2008). This low rate may be explained by a
misunderstanding of the recommendations and concerns of
doctors about the efficacy and safety of the influenza vaccine in
this population. In industrialised countries, influenza vaccines
offer B70–90% protection against clinical disease in healthy
adults, provided there is a good match between the vaccine
antigens and circulating virus(es) (Palache, 1997; Anonymous,
2005). Adults aged over 65 years typically have a diminished,
immune response to influenza vaccination compared with young
healthy adults (Jefferson et al, 2010). Response to vaccination is
probably reduced as well in patients treated with chemotherapy,
but the published data show highly variable results because of the
heterogeneity of tumours and treatments (Brydak and Machala,
2000; Brydak et al, 2001, 2006). Of note, there are no prospective
data on clinical efficacy of influenza vaccination of cancer patients.
In 2009, docetaxel (Taxotere, Sanofi-Aventis, Paris, France) was
one of the most prescribed chemotherapy, as it is an active
treatment in some of the most frequent solid tumours: lung, breast
and prostate cancers. Docetaxel is also considered as a significantly
immunosuppressive cytotoxic agent (Brain et al, 2005).
The aim of this study was to evaluate the immunogenicity
and the safety of influenza vaccination in patients receiving
chemotherapy with docetaxel.
MATERIALS AND METHODS
Study design and population
This prospective pilot study was conducted in four academic
centres in France during the 2008–2009 winter season. The main
objective of the study was to assess the immunogenicity of one
injection of a trivalent inactivated influenza vaccine.
Patients were eligible to participate in this study if they were 18
years or older and had received at least one course of docetaxel
chemotherapy for a solid tumour, whatever the stage was.
Docetaxel had to be given as a monotherapy, no other cytotoxic
drug was allowed. Docetaxel was administered at a dose of
75mgm
–2 every 3 weeks. A short treatment with corticosteroids,
up to 20mg of prednisone equivalent a day, given for an anti-
emetic purpose was accepted, as well as biotherapies with
trastuzumab or bevacizumab. Exclusion criteria included allergy
to egg proteins, previous history of allergy to any influenza vaccine
component, current acute febrile disease at the time of enrolment
or any other immunosuppressive disease (such as HIV infection,
renal insufficiency, cirrhosis).
The vaccine was administered on day 1 of docetaxel adminis-
tration. Blood samples were planned for assessment of haemag-
glutination-inhibition (Garten et al, 2009) antibodies before
vaccination, 21 days following vaccination and at month 3. Sera
were stored frozen at  201C until analysed.
Written informed consent was obtained from each patient. The
protocol was conducted in accordance with the Declaration of
Helsinki and French law for biomedical research, and was
approved by the local Ethics Committee (‘Comite ´ de Protection
des Personnes Ile-de-France III’, Paris, France).
Study vaccine
The vaccine was Vaxigrip (Sanofi-Pasteur MSD, Lyon, France), a
trivalent inactivated influenza vaccine, in single-dose presentation.
The vaccine licensed for the 2008–2009 season contained the
A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2)
and B/Malaysia/2506/2004 strains, formulated to contain 15mgo f
haemagglutinin antigen of each strain. Vaccines were pre-
packaged in 0.5ml syringes and administered intramuscularly in
the deltoid muscle using standard sterile technique.
Safety surveillance
Patients were observed for a 30-min period after immunisation to
monitor for any hypersensitivity reactions or immediate adverse
reactions. They were then provided a diary card and were
instructed to record the maximum daily measurement or
maximum severity of solicited injection site reaction (swelling,
tenderness, erythema, induration, redness) and systemic symp-
toms (fatigue, chills, malaise, myalgia, arthralgia, headache,
nausea/vomiting, sweating) for 21 days after vaccination. Patients
received the instruction to monitor their body temperature for
7 days twice daily, and report any fever happening between day
7 and day 21. Severity of vaccine-related adverse events (AEs) was
graded as mild: mild or transient discomfort, without limitation of
normal daily activities; no medical intervention or corrective
treatment required; moderate: mild-to-moderate limitation of
normal daily activities, minimal medical intervention required;
or severe: marked limitation of normal daily activities, medical
intervention and corrective treatment required, possible hospita-
lisation. Erythema and oedema at the site of injection were graded
after measurement of local reaction (mild: 0–50mm; moderate:
50–100mm; severe: 4100mm). All unsolicited AEs were recorded
for 3 months after immunisation and assessed by the investigator
for severity and relationship to the study vaccine.
Laboratory methods
Antibodies against influenza were measured using a standardised
HI assay as previously reported (Launay et al, 2008; Candon et al,
2009). HI was performed in a microtitre test using a 0.5%
suspension of O human Rhesus negative erythrocytes and four
haemagglutination units of the appropriate antigens. Monovalent
haemagglutinating antigens were generously given by Sanofi-
Pasteur, Lyon, France, and obtained from viral strains disrupted
with detergents. The stains of influenza virus studied were the A/
Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005 (H3N2)
and B/Malaysia/2506/2004. HI assays were performed in duplicate
for each sample, using serial twofold dilutions with a starting
dilution of the treated serum of 1:50 to 1:6400. The titration end
point is taken as the highest dilution that completely inhibited
haemagglutination. The lower limit of quantification was set at
1:50. Titres below this level were reported as o1:50. All the
samples of serum for each patient were analysed for HI antibodies
in a same assay.
Immunogenicity assessment
The primary end point was taken as the immunogenicity observed
21 days post-vaccination. The seroconversion rate was defined
as the proportion of patients with a fourfold or more increase
HI antibody between baseline and 21; and the seroconversion
factor as the fold increase in HI antibody titre post-vaccination
(post-vaccination antibody titre divided by the pre-vaccination
titre).
To confirm the seroconversion observed by the IHA, immuno-
genicity was assessed for the H1N1 strain by ELISA. Influenza-
specific total IgG was determined using a strain-specific antigen
capture ELISA as previously described except that the plates were
coated with the detergent disrupted A/Solomon Islands 3/2006
H1N1 strain at a dilution calculated to detect the higher optical
density (OD) with the higher dilution of serum. After washing, the
coating plates were incubated with 100ml of patients sera in
duplicate, at room temperature for 30min; after washing, the
plates were incubated in the same conditions with 100mlo fa
peroxydase-conjugated anti-human IgG (Behring, Marburg,
Germany). Plates were washed and 100ml of colorimetric substrate
TMB (Behring) was added for 30min and the reaction was stopped
by the addition of 100ml of arrest solution according to the
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smanufacturer’s instructions. Optical density of the samples was
determined at 450nM. Mean of OD40.2 between first and second
samples was considered as significant.
Statistical analysis
Descriptive and exploratory analyses were used to evaluate the
demographic characteristics stratified by different types of cancer.
The frequency and percentage of subjects who had solicited
injection site and systemic reactions were calculated. The
geometric mean of HI titres (GMT), the seroprotection rate and
the seroconversion rate were determined for each of the three
influenza vaccine strains. A 95% confidence interval (Cooksley
et al, 2005) was computed for immunogenicity parameters. Both
safety and immunogenicity data were stratified according to cancer
group. All comparisons were done using the Pearson’s w
2 test or
Fisher’s exact test for qualitative variables and the Wilcoxon’s test
for continuous variables. All tests were two-sided, and P-values
o0.05 were considered to denote statistical significance. Statistical
analyses were performed with SAS software package version 9.2
(SAS Institute, Cary, NC, USA).
RESULTS
Subjects
(Table 1) A total of 26 patients were enrolled between 25
September 2008 and 20 January 2009. One patient withdrew his
consent and did not received the vaccine; one patient was lost to
follow-up after day 1 and did not attend to the two following visits;
and two more patients were lost to follow-up after day 21 and did
not attend to the third visit (month 3). Finally, 24 subjects were
available for the day 21 immunogenicity and safety analyses, and
22 patients for the month 3 analyses. The characteristics of the
enrolled population are presented in Table 1.
Immunogenicity
(Table 2) At baseline, the GMT were ranging from 185.6 (95% CI:
125.7–274.1) for H3N2 to 358 (95% CI: 284.1–451.1) for H1N1. No
evidence of higher pre-vaccination titres was evidenced in subject
vaccinated against flu in the previous 3 years for any strains titres:
400 vs 336 for H1N1 (P¼0.73), 216 vs 138 for H3N2 (P¼0.21) and
200 vs 180 for B (P¼0.71).
By day 21 after vaccination, the seroconversion rates were
29% (95% CI: 23.1–33.3), 8% (95% CI: 7.7–8.3) and 17% (95% CI:
7.7–25); and the seroconversion factors 2.16 (95% CI: 2.10–2.22),
1.3 (95% CI: 1.26–1.34) and 1.58 (95% CI: 1.45–1.73) for the
H1N1, H3N2 and B strains, respectively.
The ELISA tests for H1N1 showed a mean OD at 0.310 at
baseline, which increased to 0.481 at day 21. All the seven patients
who have responded to the vaccine increasing their titre of
inhibiting haemagglutination antibodies have an increase of
OD40.2 between day 1 and day 21 samples (mean OD
difference¼0.330).
The age of the patients (o65 or 465 years), the level of CD4
T-cell count (o300 or 4300mm
–3) at the time of vaccination and
the previous flu vaccinations were not found as factors influencing
the seroconversion in our study. The type of cancer, which is
correlated to the use of steroids (as all prostate cancer patients
received a 10mg dose of prednisone daily), seemed to have a role
in the response to the B strain: prostate cancer patients had a
significantly better response (GMT ratio at day 21) than breast
cancer patients (P¼0.008).
Three months after vaccination, the seroprotection rates were
similar to those observed after 3 weeks.
Safety
Two patients experienced a serious AE none attributable to the
vaccine: a hyperalgic low back pain that occurred 14 weeks after
vaccination and an obstructive renal failure episode, 12 weeks after
vaccination.
No immediate AEs were reported. Nine patients (36%)
experienced AEs in the 21 days following the injection. Most of
the reported AEs were local: injection site redness (two patients),
pain at the injection site (two patients), swelling (one patient),
haematoma (one patient). Three patients reported systemic
reactions: fever (n¼1), myalgia (n¼1) and nausea (n¼1). The
patient who reported fever was a 47-year-old woman followed for a
breast cancer. She experienced fever (maximum 38.81C) during
24h, beginning 5 days after the immunisation and 1 day after a
subcutaneous injection of lenograstim (34 MUI). She did not take
any anti-pyretic drug and the fever resolved spontaneously the day
after. The link to the vaccine remains unsure. All of those AEs were
graded as mild, except one (haematoma at the site of injection)
graded as moderate and resolved spontaneously in 1–2 days. No
patients declared influenza or influenza-like illness during the
study period.
DISCUSSION
This study showed that one dose of a seasonal inactivated
influenza vaccine confers a low immune response in cancer
patients receiving docetaxel. Seroconversion rates after vaccination
were low, 28% for H1N1, 8% for H3N2 and 16% for the B strain,
and the GMT ratios were 2.16 for H1N1, 1.3 for H3N2 and 1.58 for
the B strain. There was no difference in the immune responses of
patients vaccinated in the 3 years before and those who were not.
Previous studies on the immune response to influenza vaccine
in immunosuppressed patients were hampered by small patient
numbers, the heterogeneity of the patient population included and
the criteria used for the measurement of efficacy (Anderson et al,
1999; Brydak and Machala, 2000; Brydak et al, 2001, 2006;
Table 1 Characteristics of the study population
Characteristics
Number of patients vaccinated 25
Median age, years (min–max) 65 (33–87)
Male gender, N (%) 12 (48)
Type of cancer, N (%)
Breast 13 (52)
Prostate 12 (48)
Performance status, N (%)
0 9 (36)
1 11 (44)
2 4 (16)
3 1 (4)
Median number of docetaxel courses at the
time of enrollment (min–max)
3 (1–11)
Concomitant therapy, N (%)
Corticosteroids (10mg predisone equivalent per day) 12 (48)
Hormonotherapy 1 (4)
Radiotherapy 4 (16)
GCSF use 1 (4)
Median CD4 count, cellmm
–3 (min–max) 280 (120–1790)
Previous influenza vaccination, N (%)
2007–2008 15 (60)
2006–2007 14 (56)
2005–2006 12 (48)
Abbreviation: GCSF¼granulocyte colony stimulating factor.
Influenza vaccination in cancer patients
P Loulergue et al
1672
British Journal of Cancer (2011) 104(11), 1670–1674 & 2011 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sRing et al, 2002; Vilar-Compte et al, 2006). In cancer patients not
receiving chemotherapy, the immunogenicity of the influenza
vaccine is approaching the level of healthy persons (Anderson
et al, 1999; Brydak et al, 2006). Seroprotection was generally found
between 20 and 60% in patients with solid tumours receiving
chemotherapy at the time of vaccination (Ramanathan et al, 2002).
Response rates for influenza vaccination varied between 40 and
80% for breast (Brydak et al, 2001; Vilar-Compte et al, 2006),
colorectal (Puthillath et al, 2011) and lung cancer (Anderson et al,
1999): when seroconversion rates were the criteria of efficacy,
response rate was around 40%, and when seroprotection rate was
chosen, the rates increased to 80% (Pollyea et al, 2010). There are
very few data available for prostate cancer, and we found a low
seroconversion rate in our study. The subjects analysed in those
studies were not stratified for tumour type or tumour stage,
chemotherapy schedule or vaccine type, which makes definite
conclusions difficult. However, the studies illustrated that serological
responses to different viral antigens might vary considerably between
patients and were often inferior to those noted on healthy persons. In
a recent meta-analysis on the 76 clinical studies performed between
1982 and 2006 with the trivalent subunit influenza vaccine on healthy
subjects, seroconversion rates were found between 60% and 80% for
the three strains (Giezeman et al, 2009).
The use of steroids was not found as a confounding effect in our
study, which is congruent with published data (de Roux et al,
2006).
The timing of vaccination and the chemotherapy administration
is a critical point (Boehmer et al, 2010). In this study, we chose to
vaccinate patients on the day they received their chemotherapy for
obvious practical reasons, but the best timing for immunisation
remains discussed. The only published study dealing with this
issue concluded that it was preferable to vaccinate patients
between chemotherapy courses: 36 patients, including 20 with
solid tumour, were randomised in two groups, one receiving a
bivalent whole virus influenza vaccine at the time of administra-
tion of chemotherapy and the other at the time at which blood
counts were close to their nadir. The seroconversion was better in
the group receiving the vaccine after the chemotherapy than the
other one (91 vs 56% for the solid tumour patients; Po0.05)
(Ortbals et al, 1977). The seroconversion rate for patients
vaccinated on the day of the chemotherapy was twice higher than
our rate for the H1N1 strain. Those findings should be confirmed
on an homogeneous large number of patients and with a subunit
inactivated vaccine, as whole virus influenza vaccines are known to
be more immunogenic (Hehme et al, 2004).
In this study, the seasonal influenza vaccine was well tolerated
among cancer patients. All the local or general reactions were
grade mild-to-moderate and resolved within 2 days. Although
vaccine side-effects might be expected to be tolerated poorly in
patients receiving chemotherapy, previous studies having recorded
AEs show that the vaccine was well tolerated, particularly
concerning fever, which might be confusing in such patients who
can develop febrile neutropenia (Ring et al, 2002).
The originality of our study was to include patients who had
only one type of chemotherapy and perform a prospective study on
the immunogenicity and safety of the vaccine in this homogeneous
population. The main limit of our study was the small number of
patients, due to a high rate of patient refusal (the planned sample
size was 40). This acknowledged the fact that influenza vaccine is
not accepted among cancer patients, certainly because influenza is
not recognised enough as a potential source of complications by
both patients and oncologists (Loulergue et al,2 0 0 8 ) .
Our study was a preliminary research on an important issue.
Our results showed that the inactivated trivalent influenza vaccine
was safe but induced a low immune response in patients receiving
docetaxel, confirming that those patients are very immunosup-
pressed. Efforts should be made to increase this response as those
patients need to be protected against influenza and its con-
sequences. The 2009 influenza pandemic with the variant H1N1
virus has raised the issue of the vaccination of immunosuppressed
hosts in an even more accurate way. Using adjuvants, higher dose
of antigens or more immunogenic way of vaccination, such as
intradermal injection, might constitute appropriate methods to
increase the efficacy of influenza vaccines in this population.
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